Treatment of symptomatic uterine fibroids with orally active gonadotropin-releasing hormone antagonists and add-back therapy

被引：0
|
作者：
Felberbaum, Ricardo [1 ]
Kupker, Wolfgang [2 ]
Diedrich, Klaus [3 ]
机构：
[1] Klinikverbund Allgau gGmbH, Klin Frauenheilkunde & Geburtshilfe, Klinikum Kempten & Klin Immenstadt, KinderWunschKempten KWK,Zent Gynakol Endokrinol &, Robert Weixler Str 50, D-87439 Kempten, Germany
[2] IVF Baden Baden, Zent Reprod Med & Gynakol Endokrinol, Baden Baden, Germany
[3] Univ Klinikum Schleswig Holstein, Klin Frauenheilkunde & Geburtshilfe, Campus Lubeck, Lubeck, Germany
来源：
GYNAKOLOGISCHE ENDOKRINOLOGIE | 2023年 / 21卷 / 02期
关键词：
LEIOMYOMAS;
D O I：
10.1007/s10304-023-00505-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：128 / 131
页数：4
相关论文
共 50 条
  • [31] ''Add-back'' estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri
    Davis, SR
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02): : 702 - 702
  • [32] ''Add-back'' estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri
    Sherwin, BB
    Tulandi, T
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (07): : 2545 - 2549
  • [33] Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial
    Franke, HR
    van de Weijer, PHM
    Pennings, TMM
    van der Mooren, MJ
    FERTILITY AND STERILITY, 2000, 74 (03) : 534 - 539
  • [34] Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids
    Thomas, EJ
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1996, 103 : 18 - 21
  • [35] Gonadotropin-releasing hormone agonist with add-back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis
    Lee, Dong-Yun
    Lee, Jee-Yeon
    Seo, Jong-Wook
    Yoon, Byung-Koo
    Choi, DooSeok
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 294 (06) : 1257 - 1263
  • [36] EFFECTS OF GONADOTROPIN-RELEASING HORMONE AGONIST ON UTERINE FIBROIDS AND BONE-DENSITY
    BIANCHI, G
    COSTANTINI, S
    ANSERINI, P
    ROVETTA, G
    MONTEFORTE, P
    MENADA, MV
    FAGA, L
    DECECCO, L
    MATURITAS, 1989, 11 (03) : 179 - 185
  • [37] PROLONGED GONADOTROPIN-RELEASING-HORMONE AGONIST TREATMENT OF SYMPTOMATIC ENDOMETRIOSIS - THE ROLE OF CYCLIC SODIUM ETIDRONATE AND LOW-DOSE NORETHINDRONE ADD-BACK THERAPY
    SURREY, ES
    VOIGT, B
    FOURNET, N
    JUDD, HL
    FERTILITY AND STERILITY, 1995, 63 (04) : 747 - 755
  • [38] The need for add-back with gonadotrophin-releasing hormone agonist therapy
    Studd, J
    Leather, AT
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1996, 103 : 1 - 4
  • [39] Gonadotropin-releasing hormone antagonists - Implications for oocyte quality and uterine receptivity
    Gordon, K
    HUMAN FERTILITY AND REPRODUCTION: THE OOCYTE, THE EMBRYO, AND THE UTERUS, 2001, 943 : 49 - 54
  • [40] Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
    Donnez, Jacques
    Taylor, Hugh S. S.
    Stewart, Elizabeth A. A.
    Bradley, Linda
    Marsh, Erica
    Archer, David
    Al-Hendy, Ayman
    Petraglia, Felice
    Watts, Nelson
    Gotteland, Jean-Pierre
    Bestel, Elke
    Terrill, Paul
    Loumaye, Ernest
    Humberstone, Andrew
    Garner, Elizabeth
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2022, 77 (12) : 741 - 742
12345